GENinCode Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

GENinCode şirketinin toplam hissedar öz sermayesi £2.8M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £4.7M ve £1.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£2.92m
Eşitlik	UK£2.81m
Toplam yükümlülükler	UK£1.85m
Toplam varlıklar	UK£4.66m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GENI 'nin kısa vadeli varlıkları ( £3.8M ) kısa vadeli yükümlülüklerini ( £1.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: GENI şirketinin kısa vadeli varlıkları ( £3.8M ) uzun vadeli yükümlülüklerini ( £371.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GENI borçsuzdur.

Borcun Azaltılması: GENI un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: GENI şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: GENI un, serbest nakit akışı her yıl % 42.2 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

GENinCode Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

New major risk - Market cap size

First half 2024 earnings released: UK£0.014 loss per share (vs UK£0.037 loss in 1H 2023)

New minor risk - Financial data availability

GENinCode Plc to Report First Half, 2024 Results on Sep 25, 2024

GENinCode Plc, Annual General Meeting, Jun 27, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: UK£0.07 loss per share (vs UK£0.058 loss in FY 2022)

GENinCode Plc to Report Fiscal Year 2023 Results on Jun 03, 2024

New minor risk - Financial data availability

GENinCode Plc Announces Publication by the American Journal of Preventive Cardiology of A Study on 'Polygenic Risk and Incident Heart Disease in a Large Multiethnic Cohort

New major risk - Share price stability

GENinCode Plc has completed a Follow-on Equity Offering in the amount of £4.057378 million.

GENinCode plc Agrees with the Food and Drug Administration to Create New Regulatory Class for Polygenic Risk scores and Transition Its Premarket Notification 510(K) Submission to A De Novo Pathway

New major risk - Market cap size

First half 2023 earnings released: UK£0.037 loss per share (vs UK£0.024 loss in 1H 2022)

GENinCode Plc Provides Revenue Guidance for the Second Half of 2023

GENinCode Plc Provides Revenue Guidance for the Second Half of 2023

GENinCode Plc to Report First Half, 2023 Results on Sep 20, 2023

Genincode plc Announces CARDIO inCode study on risk of incident Coronary Heart Disease

GENinCode plc Files its Premarket Notification (510k) with the Food and Drug Administration to Expand Its US Commercial Distribution of the Cardio InCode-Score Polygenic Test for the Risk Assessment and Prevention of Coronary Heart Disease

New major risk - Financial position

GENinCode Plc, Annual General Meeting, Jun 30, 2023

Full year 2022 earnings: Revenues exceed analyst expectations

GENinCode Plc to Report Fiscal Year 2022 Results on Jun 06, 2023

Genincode plc Announces Approval of California State License and Clia Certification Opens Us Market

High number of new directors

First half 2022 earnings released: UK£0.027 loss per share (vs UK£0.088 loss in 1H 2021)

GENinCode plc, Annual General Meeting, Jun 23, 2022

Full year 2021 earnings: Revenues miss analyst expectations

GENinCode plc to Report Fiscal Year 2021 Results on May 17, 2022

Less than half of directors are independent

Less than half of directors are independent

Genincode plc Announces the Appointment of Felix Frueh, as Non-Executive Director

Genincode plc Appoints Huon Gray Cbe as an Independent Non-Executive Director

GENinCode plc Provides Positive Results for Lipid InCode in NHS Study

GENinCode Plc Announces FDA Pre-Submission for Cardio inCode-Score

Less than half of directors are independent

Independent Non-Executive Director David Evans has left the company

GENinCode plc (AIM:GENI) acquired Assets of Ferrer inCode and Gendiag.exe Businesses from Grupo Ferrer Internacional, S.A.

GENinCode Plc has completed an IPO in the amount of £17.000001 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin